Table 3.

Response to Protocol Therapy

Patient No.	Disease Characteristics	Single-Agent Epratuzumab (reduction phase)					Epratuzumab + Block 1 Chemotherapy
		Absolute Blast Count (per μL)		Marrow Blast (%)
		Pre	Post	Pre	Post	Response	Response	MRD
1	1st early M	440	34	57	11	SD	ND*	ND*
2	1st late M + CNS	328	0	94	84	SD	CR	Negative
3	2nd M + CNS	9400	< 300	90	95	SD	ND*	ND*
4	1st early M	2016	0	71	34	PRCL	CR	Negative
5	2nd M + CNS	384	66	85	37	SD	CR	Negative
6	2nd M	< 100	0	90	96	SD	SD	Positive
7	2nd M	0	0	84	73	SD	CR	Negative
8	1st late M + T	544	300	91	90	SD	CR	Positive
9	1st early M	1863	ND†	83	ND†	PD	ND†	ND†
10	1st early M	0	0	70	89	SD	CR	Negative
11	1st early M	0	55,088	81	88	PD	PD	Positive
12	1st early M	130	34,875	39	ND‡	PD	PR	Positive
13	1st late M	1442	0	90	86	SD	CR	Negative
14	1st late M + CNS	2000	1000	98	82	SD	CR	Negative
15	1st early M	0	0	65	34	SD	CR	Positive

Disease characteristics: M, marrow; T, testicular; CR, complete remission; PR, partial response; PRCL, partial remission cytolytic; SD, stable disease; PD, progressive disease; ND, not done.

^*Death during block 1.

^†Patient removed from study after one dose of epratuzumab.

^‡Patient did not complete reduction phase because of PD.